U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Polymyxin B is a lipopeptide antibiotic isolated from Bacillus polymyxa. Its basic structure consists of a polycationic peptide ring and a tripeptide side chain with a fatty acid tail. Polymyxin B is a mixture of at least four closely related components, polymyxin B1 to B4, with polymyxin B1 and B2 being the two major components. Polymyxin B acts on Gram-negative bacteria by interacting with lipopolysaccharide (LPS) of the outer membrane and destabilizing it. Polymyxin B is indicated for the treatment of many bacterial diseases such as meningeal infections, urinary tract infections and bacteremia.

CNS Activity

Curator's Comment: Polymyxin B penetrates BBB and cause neurotoxic effect.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q28824
Gene ID: 338037.0
Gene Symbol: MYLK
Target Organism: Bos taurus (Bovine)
70.0 µM [IC50]
Target ID: Protein kinase C (Bos taurus)
4.0 µM [IC50]
800.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
POLYMYXIN B SULFATE

Approved Use

Acute infections caused by susceptible strains of Pseudomonas aeruginosa.

Launch Date

1964
Curative
POLYMYXIN B SULFATE

Approved Use

Acute infections caused by susceptible strains of Pseudomonas aeruginosa.

Launch Date

1964
Curative
POLYMYXIN B SULFATE

Approved Use

Acute infections caused by susceptible strains of Pseudomonas aeruginosa.

Launch Date

1964
Curative
POLYMYXIN B SULFATE

Approved Use

Acute infections caused by susceptible strains of Pseudomonas aeruginosa.

Launch Date

1964
PubMed

PubMed

TitleDatePubMed
COMPARISON OF THE ACTION OF STREPTOMYCIN, POLYMYXIN B, AUREOMYCIN AND CHLOROMYCETIN ON H. PERTUSSIS, H. PARAPERTUSSIS, H. INFLUENZAE AND FIVE ENTERIC STRAINS OF GRAM-NEGATIVE BACILLI.
1949 Sep
LABORATORY AND CLINICAL STUDIES OF POLYMYXIN B AND E.
1949 Sep
Evolution and dynamics of regulatory architectures controlling polymyxin B resistance in enteric bacteria.
2008 Oct
Evolution and dynamics of regulatory architectures controlling polymyxin B resistance in enteric bacteria.
2008 Oct
Successful treatments with polymyxin B hemoperfusion and recombinant human thrombomodulin for fulminant Clostridium difficile-associated colitis with septic shock and disseminated intravascular coagulation: a case report.
2016 Dec
The effects of direct hemoperfusion using a polymyxin B-immobilized column in a pig model of severe Pseudomonas aeruginosa pneumonia.
2016 Dec
A feed-forward loop between SroC and MgrR small RNAs modulates the expression of eptB and the susceptibility to polymyxin B in Salmonella Typhimurium.
2016 Nov
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: 25,000 to 30,000 units/kg/day (Intramuscular injection), 50,000 units once daily intrathecally for 3 to 4 days, then 50,000 units once every other day for at least 2 weeks (Intrathecal injection).
15,000 to 25,000 units/kg body weight/day
Route of Administration: Intravenous
Polymyxin B MICs were determined for different strains of P. aeruginosa in Ca-MHB using a broth macrodilution method. The MIC was defined as the lowest concentration of drug that resulted in no visible growth after 24 h of incubation at 35°C in ambient air. The polymyxin B MIC ranged from 0.5 to 1 mg/liter.
Name Type Language
POLYMYXIN B
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
POLYMYXIN B [VANDF]
Common Name English
polymyxin b [INN]
Common Name English
Polymyxin b [WHO-DD]
Common Name English
POLYMYXIN B [MI]
Common Name English
POLYSPORIN COMPONENT POLYMYXIN B
Brand Name English
POLYMIXIN B
Common Name English
Classification Tree Code System Code
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-VATC QA07AA05
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-VATC QS03AA03
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-VATC QS01AA18
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-ATC S03AA03
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-ATC J01XB02
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-VATC QJ01XB02
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-ATC A07AA05
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
CFR 21 CFR 524.155
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-ATC S02AA11
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-VATC QS02AA11
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
NDF-RT N0000175499
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
CFR 21 CFR 333.120
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
CFR 21 CFR 524.1484E
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
CFR 21 CFR 524.1445
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
CFR 21 CFR 524.1662B
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-ATC S01AA18
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
CFR 21 CFR 524.960
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
NCI_THESAURUS C78160
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
NDF-RT N0000007822
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
CFR 21 CFR 524.1484H
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
WHO-VATC QJ51XB02
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
CFR 21 CFR 524.154
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
Code System Code Type Description
DAILYMED
J2VZ07J96K
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
MESH
D011112
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
EPA CompTox
DTXSID1048467
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
ECHA (EC/EINECS)
215-768-4
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
WIKIPEDIA
POLYMYXIN B
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
EVMPD
SUB03937MIG
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
FDA UNII
J2VZ07J96K
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
CAS
1404-26-8
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
MERCK INDEX
m8963
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY Merck Index
DRUG BANK
DB00781
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
NCI_THESAURUS
C61894
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
RXCUI
8536
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY RxNorm
DRUG CENTRAL
4246
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
INN
490
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
LACTMED
Polymyxin B
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201283
Created by admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
PRIMARY
Definition References